Objective evidence for the reversibility of nerve injury in diabetic neuropathic cachexia.
Grewal
Jaspreet
J
Bril
Vera
V
Lewis
Gary F
GF
Lewis
Gary
G
Perkins
Bruce A
BA
D000328:Adult; D000588:Amines / Q000627:therapeutic use; D000639:Amitriptyline / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D002100:Cachexia / Q000209:etiology / Q000628:therapy*; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D003929:Diabetic Neuropathies / Q000150:complications / Q000188:drug therapy*; D005260:Female; D000077206:Gabapentin; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D007328:Insulin / Q000009:adverse effects / Q000627:therapeutic use; D009431:Neural Conduction / Q000187:drug effects; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
D000588:Amines; D000700:Analgesics; D000929:Antidepressive Agents, Tricyclic; D003509:Cyclohexanecarboxylic Acids; D007004:Hypoglycemic Agents; D007328:Insulin; D000639:Amitriptyline; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin